NCT04417192View on ClinicalTrials.gov

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib

Olaparib will be administered at a dose of 300mg as oral dose, twice a day.

DRUG

Pembrolizumab

Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).

Trial Locations (3)

Unknown

National Cancer Center Hospital East, Kashiwa

National Hospital Organization Shikoku Cancer Center, Matsuyama

Kurume University Hospital, Kurume

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National Cancer Center Hospital East

OTHER

NCT04417192 - Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer | Biotech Hunter | Biotech Hunter